Cargando…
Targeting the Two Oncogenic Functional Sites of the HPV E6 Oncoprotein with a High-Affinity Bivalent Ligand**
The E6 oncoproteins of high-risk mucosal (hrm) human papillomaviruses (HPVs) contain a pocket that captures LxxLL motifs and a C-terminal motif that recruits PDZ domains, with both functions being crucial for HPV-induced oncogenesis. A chimeric protein was built by fusing a PDZ domain and an LxxLL m...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
WILEY-VCH Verlag
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4512291/ https://www.ncbi.nlm.nih.gov/pubmed/26014966 http://dx.doi.org/10.1002/anie.201502646 |
_version_ | 1782382473103015936 |
---|---|
author | Ramirez, Juan Poirson, Juline Foltz, Clémence Chebaro, Yassmine Schrapp, Maxime Meyer, Amandine Bonetta, Anaëlle Forster, Anne Jacob, Yves Masson, Murielle Deryckère, François Travé, Gilles |
author_facet | Ramirez, Juan Poirson, Juline Foltz, Clémence Chebaro, Yassmine Schrapp, Maxime Meyer, Amandine Bonetta, Anaëlle Forster, Anne Jacob, Yves Masson, Murielle Deryckère, François Travé, Gilles |
author_sort | Ramirez, Juan |
collection | PubMed |
description | The E6 oncoproteins of high-risk mucosal (hrm) human papillomaviruses (HPVs) contain a pocket that captures LxxLL motifs and a C-terminal motif that recruits PDZ domains, with both functions being crucial for HPV-induced oncogenesis. A chimeric protein was built by fusing a PDZ domain and an LxxLL motif, both known to bind E6. NMR spectroscopy, calorimetry and a mammalian protein complementation assay converged to show that the resulting PDZ-LxxLL chimera is a bivalent nanomolar ligand of E6, while its separated PDZ and LxxLL components are only micromolar binders. The chimera binds to all of the hrm-HPV E6 proteins tested but not to low-risk mucosal or cutaneous HPV E6. Adenovirus-mediated expression of the chimera specifically induces the death of HPV-positive cells, concomitant with increased levels of the tumour suppressor P53, its transcriptional target p21, and the apoptosis marker cleaved caspase 3. The bifunctional PDZ-LxxLL chimera opens new perspectives for the diagnosis and treatment of HPV-induced cancers. |
format | Online Article Text |
id | pubmed-4512291 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | WILEY-VCH Verlag |
record_format | MEDLINE/PubMed |
spelling | pubmed-45122912015-08-19 Targeting the Two Oncogenic Functional Sites of the HPV E6 Oncoprotein with a High-Affinity Bivalent Ligand** Ramirez, Juan Poirson, Juline Foltz, Clémence Chebaro, Yassmine Schrapp, Maxime Meyer, Amandine Bonetta, Anaëlle Forster, Anne Jacob, Yves Masson, Murielle Deryckère, François Travé, Gilles Angew Chem Int Ed Engl Communications The E6 oncoproteins of high-risk mucosal (hrm) human papillomaviruses (HPVs) contain a pocket that captures LxxLL motifs and a C-terminal motif that recruits PDZ domains, with both functions being crucial for HPV-induced oncogenesis. A chimeric protein was built by fusing a PDZ domain and an LxxLL motif, both known to bind E6. NMR spectroscopy, calorimetry and a mammalian protein complementation assay converged to show that the resulting PDZ-LxxLL chimera is a bivalent nanomolar ligand of E6, while its separated PDZ and LxxLL components are only micromolar binders. The chimera binds to all of the hrm-HPV E6 proteins tested but not to low-risk mucosal or cutaneous HPV E6. Adenovirus-mediated expression of the chimera specifically induces the death of HPV-positive cells, concomitant with increased levels of the tumour suppressor P53, its transcriptional target p21, and the apoptosis marker cleaved caspase 3. The bifunctional PDZ-LxxLL chimera opens new perspectives for the diagnosis and treatment of HPV-induced cancers. WILEY-VCH Verlag 2015-06-26 2015-05-26 /pmc/articles/PMC4512291/ /pubmed/26014966 http://dx.doi.org/10.1002/anie.201502646 Text en © 2015 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA. This is an open access article under the terms of the Creative Commons Attribution Non-Commercial NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. https://creativecommons.org/licenses/by-nc-nd/4.0/ © 2015 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA. This is an open access article under the terms of the Creative Commons Attribution Non-Commercial NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Communications Ramirez, Juan Poirson, Juline Foltz, Clémence Chebaro, Yassmine Schrapp, Maxime Meyer, Amandine Bonetta, Anaëlle Forster, Anne Jacob, Yves Masson, Murielle Deryckère, François Travé, Gilles Targeting the Two Oncogenic Functional Sites of the HPV E6 Oncoprotein with a High-Affinity Bivalent Ligand** |
title | Targeting the Two Oncogenic Functional Sites of the HPV E6 Oncoprotein with a High-Affinity Bivalent Ligand** |
title_full | Targeting the Two Oncogenic Functional Sites of the HPV E6 Oncoprotein with a High-Affinity Bivalent Ligand** |
title_fullStr | Targeting the Two Oncogenic Functional Sites of the HPV E6 Oncoprotein with a High-Affinity Bivalent Ligand** |
title_full_unstemmed | Targeting the Two Oncogenic Functional Sites of the HPV E6 Oncoprotein with a High-Affinity Bivalent Ligand** |
title_short | Targeting the Two Oncogenic Functional Sites of the HPV E6 Oncoprotein with a High-Affinity Bivalent Ligand** |
title_sort | targeting the two oncogenic functional sites of the hpv e6 oncoprotein with a high-affinity bivalent ligand** |
topic | Communications |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4512291/ https://www.ncbi.nlm.nih.gov/pubmed/26014966 http://dx.doi.org/10.1002/anie.201502646 |
work_keys_str_mv | AT ramirezjuan targetingthetwooncogenicfunctionalsitesofthehpve6oncoproteinwithahighaffinitybivalentligand AT poirsonjuline targetingthetwooncogenicfunctionalsitesofthehpve6oncoproteinwithahighaffinitybivalentligand AT foltzclemence targetingthetwooncogenicfunctionalsitesofthehpve6oncoproteinwithahighaffinitybivalentligand AT chebaroyassmine targetingthetwooncogenicfunctionalsitesofthehpve6oncoproteinwithahighaffinitybivalentligand AT schrappmaxime targetingthetwooncogenicfunctionalsitesofthehpve6oncoproteinwithahighaffinitybivalentligand AT meyeramandine targetingthetwooncogenicfunctionalsitesofthehpve6oncoproteinwithahighaffinitybivalentligand AT bonettaanaelle targetingthetwooncogenicfunctionalsitesofthehpve6oncoproteinwithahighaffinitybivalentligand AT forsteranne targetingthetwooncogenicfunctionalsitesofthehpve6oncoproteinwithahighaffinitybivalentligand AT jacobyves targetingthetwooncogenicfunctionalsitesofthehpve6oncoproteinwithahighaffinitybivalentligand AT massonmurielle targetingthetwooncogenicfunctionalsitesofthehpve6oncoproteinwithahighaffinitybivalentligand AT deryckerefrancois targetingthetwooncogenicfunctionalsitesofthehpve6oncoproteinwithahighaffinitybivalentligand AT travegilles targetingthetwooncogenicfunctionalsitesofthehpve6oncoproteinwithahighaffinitybivalentligand |